Risk factors
Clene (CLNN) risk factors
Item 1A of every Clene Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors68 risks2 reworded
Operating loss decreased to $23.1 million in 2025 from $33.1 million in 2024, but accumulated deficit grew to $308.3 million.
Filed Mar 17, 2026 - FY2024 10-K risk factors68 risks
Clene relies heavily on the commercialization of its lead drug candidate CNM-Au8, an emerging gold nanocrystal suspension for neurological diseases. The company faces significant risks from ongoing net losses, manufacturing self-dependence, regulatory approvals, and patient enrollment challenges.
Filed Mar 24, 2025